Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 12Neuroendocrine Tumors 5Neoplasm Metastasis 5Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Adenoma, Islet Cell 3Recurrence 2Meningioma 2Glioblastoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Thymus Neoplasms 1Sarcoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphangioleiomyomatosis 1Locally Advanced Thyroid Gland Carcinoma 1Kidney Neoplasms 1HR+/HER2- Advanced Breast Cancer 1Glioma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Gallbladder Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Digestive System Neuroendocrine Tumor G1 × Everolimus × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡